- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Interventions
- Durvalumab, Sirolimus
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 3,556
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Vandetanib, Erlotinib
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,574 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 29
- States / cities
- Berkeley, California • Los Angeles, California • Santa Rosa, California + 26 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- BMS-986504, Izalontamab Brengitecan
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 10
- States / cities
- Anchorage, Alaska • Boston, Massachusetts • Detroit, Michigan + 6 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
- Interventions
- Durvalumab, Radiation Therapy, Biospecimen Collection
- Biological · Radiation · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 11
- States / cities
- Baltimore, Maryland • City of Saint Peters, Missouri • St Louis, Missouri + 7 more
- Conditions
- Non-small Cell Lung Cancer Stage I
- Interventions
- Ad5-yCD/mutTKSR39rep-ADP Adenovirus
- Biological
- Lead sponsor
- Benjamin Movsas, M.D.
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma, Mesothelioma, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Pleura, Metastatic Malignant Neoplasm in the Spinal Cord, Non-Small Cell Lung Carcinoma, Sarcoma, Small Cell Lung Carcinoma, Thymic Carcinoma, Thymoma, Thyroid Gland Carcinoma
- Interventions
- Doxepin Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin
- Conditions
- Lung Cancer
- Interventions
- radiation therapy
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 224
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 175 more
- Conditions
- Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer
- Interventions
- allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa, recombinant interferon gamma, sargramostim, cyclophosphamide
- Biological · Drug
- Lead sponsor
- St. Vincent Medical Center - Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lung Cancer
- Interventions
- trastuzumab, carboplatin, paclitaxel
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 68
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 51 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Stereotactic Body Radiation Therapy
- Radiation
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
- Interventions
- Durvalumab, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, External beam radiation (dose level 1), External beam radiation (dose level 2), External beam radiation (hyperfractionated), Cisplatin (dose level 1), Cisplatin (dose level 2), External beam radiation (standard)
- Drug · Radiation
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Aurora, Colorado • Houston, Texas
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Nonmalignant Neoplasm, Precancerous Condition
- Interventions
- bronchoscopic and lung imaging studies, diagnostic bronchoscopy, histopathologic examination, optical coherence tomography
- Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Circulating tumor cell chip
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- DV281, Breath Actuated Nebulizer, DV281 (RP2D), Approved Anti-PD-1 Inhibitor
- Drug · Device
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- La Jolla, California • Santa Monica, California • Minneapolis, Minnesota + 3 more
- Conditions
- Carcinoma, Non-small-cell Lung
- Interventions
- Tarceva (erlotinib HCl, OSI-774 )
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Seattle, Washington
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Interventions
- Ipilimumab, Placebo, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 24 more
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer
- Interventions
- XMT-2056
- Drug
- Lead sponsor
- Day One Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Stanford, California • Celebration, Florida + 8 more
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- ASP388B, Pembrolizumab, Carboplatin, Oxaliplatin, 5-fluorouracil
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Lake Success, New York • Fairfax, Virginia
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
- Interventions
- GDC-6036, Atezolizumab, Cetuximab, Bevacizumab, Erlotinib, GDC-1971, Inavolisib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 9
- States / cities
- Duarte, California • La Jolla, California • Orange, California + 6 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Docetaxel
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Irvine, California • Los Alamitos, California • Orange, California + 3 more
- Conditions
- Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent
- Interventions
- Nivolumab, nab-paclitaxel
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Edgewood, Kentucky • Saint Louis Park, Minnesota • St Louis, Missouri + 1 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 6
- States / cities
- Elizabeth, New Jersey • Summit, New Jersey • Toms River, New Jersey + 3 more
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Recurrent Non Small Cell Lung Cancer
- Interventions
- Garmin Vivofit Activity Tracker
- Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Chambersburg, Pennsylvania • Ephrata, Pennsylvania • Gettysburg, Pennsylvania + 2 more